0001209191-21-037377.txt : 20210602 0001209191-21-037377.hdr.sgml : 20210602 20210602180753 ACCESSION NUMBER: 0001209191-21-037377 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210528 FILED AS OF DATE: 20210602 DATE AS OF CHANGE: 20210602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schroeder Thilo CENTRAL INDEX KEY: 0001776412 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39539 FILM NUMBER: 21990531 MAIL ADDRESS: STREET 1: C/O PELOTON THERAPEUTICS, INC. STREET 2: 2330 INWOOD ROAD, SUITE 226 CITY: DALLAS STATE: TX ZIP: 75235 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001699382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463218129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 642-6664 MAIL ADDRESS: STREET 1: 8 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-28 0 0001699382 PMV Pharmaceuticals, Inc. PMVP 0001776412 Schroeder Thilo C/O PMV PHARMACEUTICALS, INC. 8 CLARKE DRIVE, SUITE 3 CRANBURY NJ 08512 1 0 0 0 Common Stock 2021-05-28 4 S 0 5100 35.80 D 2038529 I See footnote Shares were sold pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.61 to 36.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. /s/ Darren DeStefano, Attorney-in-Fact 2021-06-02